[포스트 IPO]② 루닛, 관리종목 리스크 사정권…흑전 목표시점 당겼다

Lunit, a Korean healthcare AI company that went public in 2022, faces a critical credibility crisis as its rapid revenue growth has failed to translate into profitability, causing its stock price to collapse from 200,000 won to under 20,000 won. The company now confronts imminent delisting risk under Korea Exchange's accumulated loss regulations, forcing it to accelerate profitability timelines and implement aggressive cost-cutting measures including 20% workforce reductions. This case exemplifies the fundamental challenge for high-growth biotech startups to balance aggressive expansion with financial sustainability, particularly in heavily regulated medical device sectors with inherently long commercialization cycles.